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309 The use of a volumetric infusion device for intravenous antibiotic
desensitisation in cystic ﬁbrosis
M. Butler1, K. Thompson2, D. Watson1, L. Kuitert1. 1The London Chest Hospital,
London, United Kingdom; 2Royal Brompton & Hareﬁeld NHS Foundation Trust,
London, United Kingdom
Objective: To investigate an alternative method of intravenous (IV) antibiotic
desensitisation in patients with cystic ﬁbrosis (CF).
The use of IV antibiotics is a central part of the management of pulmonary
infections in CF. Allergic reactions to antibiotics are more common in patients
with CF in part due to repeated exposure to high doses [1]. Desensitisation, an
established procedure in CF allows use of these antibiotics in all but severe allergic
reaction through induction of temporary immune tolerance. Desensitisation involves
a 7 step administration of incremental doses of antibiotic. Doses are made by our
pharmacy department, require 24 hours notice for production and the service is
costly.
Method: We developed a protocol to use a volumetric infusion device (VID) to
administer established 7 step desensitisation regimens. Desensitisations using the
VID were prepared and administered by a clinical nurse specialist.
Results: Over 5 months 9 patients received IV antibiotic desensitisation using a
VID. This was successful in all but 1 patient. The ﬂow rate for Step 7 of the original
desensitisation regimen was reduced as this ﬂow rate could not be administered in
patients with TIVADs. The use of a VID allowed greater ﬂexibility in the timing and
frequency of desensitisation. There was no delay in treatment for patients requiring
desensitisation when the VID was used.
Conclusion: A 7 step IV antibiotic desensitization programme using a VID is well
tolerated, safe and cost effective. The use of a VID can reduce delay in patients
with drug allergies receiving IV antibiotics.
Reference(s)
[1] J S Parmar, S Nasser. Antibiotic allergy in cystic ﬁbrosis. Thorax 2005; 60: 517–
520.
310 Detecting health changes in Omani children with cystic
ﬁbrosis (CF), using a novel nurse-led questionnaire
C. Norrish1, U. Fass1, G. Shivalingam2, M. Al Salmani1, M. Norrish3, H. Kallesh2,
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Background: Little research has been done on CF in Oman. With no specialist CF
centers yet it is not surprising that survival rates are still well below international
standards. Overcoming cultural and communication barriers may play an important
part in understanding how CF affects this unique population.
Objectives: Pulmonary Exacerbations (PEx) are known to have a negative impact
on health status in children with CF. This study aims to determine if a novel nurse-
led questionnaire (NQ) detects changes in the health status of individual Omani
children with CF.
Methods: 9 children ranging from 2−16 years (mean 7.5) were assessed using the
NQ during outpatient visits. The NQ, in Arabic, was based on published indicators
of PEx, and utilized a variety of visual analogue and likert scales. Items include
patient-reported changes in cough, sputum production, breathing, activity/energy
levels, and appetite during the previous week. The total NQ score (NQS) were then
compared with objective clinical measures.
Results: The NQS is signiﬁcantly higher for admitted patients, t(69) = 5.1, p< 0.001
(mean 53.6, cf 34.8 for non-admitted). Clinical measures are signiﬁcantly related to
the NQS, with increased abnormal chest sounds in patients having a spike in their
NQS, t(58) = 3.03, p< 0.01. BMI is signiﬁcantly correlated with NQS (R=−0.4,
p< 0.001).
Conclusion: The NQ is a useful and sensitive tool, indicating changes in the
individual health status of these patients. This nurse-led approach to monitoring
health status provides a unique and contextually appropriate opportunity for bilateral
communication and patient education within a developing CF care setting.
311 Do quality of life responses signal severe loss of lung function?
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Objectives: Severe loss of lung function increases morbidity in CF. Purpose of the
study was to evaluate quality of life factors preceding a loss of lung function.
Methods: 68 CF patients (29 female; age range 14−57 yrs). The Cystic Fibrosis
Quality of Life Questionnaire (CFQ-R) was administered annually during routine
visits of outpatients. At the ﬁrst assessment condition of all patients was stable with
mild lung function impairment (2010). At the second assessment (2011) two groups
were deﬁned: Sample 1: 18 patients with loss of lung function 10%. Sample 2:
50 patients with minor loss of lung function. In a second analysis patients were
split into three age groups: A: 14−18 yrs; B: 18−25; C: >25.
Results: In retrospect, we found signiﬁcant differences in HQL in Sample 1 one
year prior to loss of lung function. When samples were compared according to
age groups, in sample 1 group A described more emotional problems (m= 64.4 vs
72.2) and treatment-related problems (m= 21.1 vs 27.8). Group B scored lower on
scales: physical functioning (m= 73.0 vs 84.7), body image (m= 73.6 vs 92.6), role
performance (m= 73.6 vs 93.6) and health perception (m= 13.6 vs 55.5). Group C
reported lower health perception (m= 18.5 vs 47.8) and energy (m= 55.8 vs 66.1).
Conclusion: Perceived health-related quality of life might be an early sign for
illness progression. Possible predictors seem to be age-dependent. Further studies
to support the preliminary results are ongoing.
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Objectives: The Cystic Fibrosis Questionnaire-Revised (CFQ-R) can help measure
how the CF population responds to disease severity and the burden of therapy.
To date, the CF patients of Newfoundland and Labrador (NL) have not had their
health-related quality of life (HRQoL) assessed. The purpose of this study was to
establish the baseline HRQoL of these patients and determine how variables such
as FEV1, access to private insurance or optimal therapy, and chronic colonization
with Pseudomonas aeruginosa (PA) affect HRQoL.
Methods: The CFQ-R was administered to all adult and adolescent CF patients in
NL between June and August 2012. Patients consented and completed the survey
in clinic. Descriptive statistics were generated for variables of interest. Survey
responses were categorized by breaking survey domains into 25% (patients feels
poorly about the domain), 26−75% (patient feels moderately good) and 76%
(patient feels positively).
Conclusion: Thirty-eight patients (63%) consented and completed the survey. 66%
were males, 34% females, mean age was 30 years, mean FEV1 was 64%. Half had
private insurance and 55% were chronically colonized with PA. Mean scores of the
38 patients for the CFQ-R ranged from 51 to 91 (out of 100). Patients with higher
FEV1 generally scored higher in all domains. Numerical diiferences were seen in 5
of 12 domains (physical, health perception, body image, weight and digestion) when
comparing access to private insurance. Those with PA scored worse in all domains
except for 3 (social, role and digestion). Numerical differences were also seen in 4
domains (physical, health perception, social and digestion) when comparing access
to optimal therapy.
